Maple syrup urine disease diagnosis in Brazilian patients by massive parallel sequencing
Rafael Hencke Tresbach,Fernanda Sperb-Ludwig,Rodrigo Ligabue-Braun,Fernanda Hendges de Bitencourt,Tássia Tonon,Carolina Fischinger Moura de Souza,Fabiano de Oliveira Poswar,Maria Efigênia de Queiroz Leite,Tatiana Amorim,Gilda Porta,João Seda Neto,Irene Kazumi Miura,Carlos Eduardo Steiner,Ana Maria Martins,André Luiz Santos Pessoa,Erlane Marques Ribeiro,Ida Vanessa Doederlein Schwartz
DOI: https://doi.org/10.1016/j.ymgme.2024.108569
Abstract:Biallelic pathogenic variants cause maple syrup urine disease (MSUD) in one of the branched-chain α-keto acid dehydrogenase (BCKDH) complex genes (BCKDHA, BCKDHB, DBT, DLD, and PPM1K) leading to the accumulation of leucine, isoleucine, and valine. This study aimed to perform a molecular diagnosis of Brazilian patients with MSUD using gene panels and massive parallel sequencing. Eighteen Brazilian patients with a biochemical diagnosis of MSUD were analyzed by massive parallel sequencing in the Ion PGM Torrent Server using a gene panel with the BCKDHA, BCKDHB, and DBT genes. The American College of Medical Genetics and Genomics guidelines were used to determine variant pathogenicity. Thirteen patients had both variants found by massive parallel sequencing, whereas 3 patients had only one variant found. In 2 patients, the variants were not found by this analysis. These 5 patients required additional Sanger sequencing to confirm their genotype. Twenty-five pathogenic variants were identified in the 3 MSUD-related genes (BCKDHA, BCKDHB, and DBT). Most variants were present in the BCKDHB gene, and no common variants were found. Nine novel variants were observed: c.922 A > G, c.964C > A, and c.1237 T > C in the BCKDHA gene; and c.80_90dup, c.384delA, c.478 A > T, c.528C > G, c.977 T > C, and c.1039-2 A > G in the BCKDHB gene. All novel variants were classified as pathogenic. Molecular modeling of the novel variants indicated that the binding of monomers was affected in the BCKDH complex tetramer, which could lead to a change in the stability and activity of the enzyme. Massive parallel sequencing with targeted gene panels seems to be a cost-effective method that can provide a molecular diagnosis of MSUD.